It should be emphasised that currently there are no indications for the preventive use of lipid-lowering agents solely on the basis of the presence of autoimmune diseases, rheumatic diseases, or diseases of inflammatory aetiology, and prevention and treatment of dyslipidaemia does not differ from general rules of management in this regard
Mutations in the LRRK2 gene, particularly the most common Gly2019Ser mutation, are seen in patients with autosomal-dominant PD and patients with apparently sporadic PD, who are clinically indistinguishable from patients with idiopathic PD [100]
They are proposed to trigger the disease process by activating glial cells, impairing synaptic plasticity, and inducing neuronal toxicity
Moreover, LA may enhance fatty acid oxidation by modulating the PPAR pathway, as activated PPAR induces the expression of genes related to fatty acid oxidation [74]